Navigation Links
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Date:10/19/2009

PHILADELPHIA, Oct. 19 /PRNewswire/ -- New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

"New data demonstrate sustained efficacy of golimumab dosed every four weeks in patients with RA who were previously treated with anti-TNF agents," said Dr. Jonathan Kay, Professor of Medicine and Director of Clinical Research in the Rheumatology Division at the University of Massachusetts Medical School in Worcester, Massachusetts and lead study investigator.

Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study demonstrated that patients with RA previously treated with adalimumab, etanercept or infliximab responded to, and maintained response to, SIMPONI through one year. At week 52, 63 percent of patients receiving SIMPONI 50 mg achieved at least a 20 percent improvement in arthritis signs and symptoms as measured by American College of Rheumatology (ACR 20) response, and 41 percent achieved a 50 percent improvement in arthritis signs and symptoms as measured by ACR 50 response.

SIMPONI-treated patients who had discontinued previous anti-TNF treatment for any reason sustained improvements in physical function, as measured by the Health Assessment Questionnaire (HAQ). At week 52, patients receiving SIMPONI 50 mg maintained a clinically relevant improvement (decrease in HAQ score of at least 0.25) from baseline. Similar results were previously reported at week 24. HAQ assesses the degree of difficulty a person has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching,
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel
3. Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
4. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
7. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
8. The Institut Pasteur and Merieux Alliance Take First Step Towards a Long-Term Research Partnership in the Field of Infectious Diseases
9. Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes
10. Cord Blood America Further Reduction, $817,000, in Long-Term Debt
11. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... ... its 2015 growth plan and as a follow up to the recently announced expansion of ... pleased to announce that it has begun construction on a new Microbiological Laboratory. The new ... dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw materials. ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional performance in ... , as well as solid contributions from Korea, India ... Middle East / Africa (Q2 2015: ... , Turkey and the United Kingdom ... excluding U.S. HPV sales, on demand across all customer classes. The top seven ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... , ... (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits and Risks ... , ... 2009 -- The Drug Information Association (DIA) and the US Food and Drug ...
... ... Products announced a financial support partnership with several key vendors to ... collective effort with a dedicated "Pink" section on their website, ... will be available. Spectrum will also donate $1 per order ...
... Inc. (OTC Bulletin Board: BTEL) announced results for the fiscal ... or $0.33 per diluted share, on revenues of $12,640,000. ... diluted share on revenues of $11,495,000 in fiscal year 2008. ... of $174,000 or $0.06 per diluted share, on revenues of ...
Cached Biology Technology:Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 2Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop 3Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 2Spectrum Announces Support Partnership for Breast Cancer Research During Breast Cancer Awareness Month 3Biotel Announces Fourth Quarter and Year End Results 2
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 /PRNewswire/ ... today announced BD & Guidepoint Mentor, a ... access to Guidepoint,s expert network services. ... cutting-edge technologies to improve healthcare delivery and outcomes and, ... each start-up entrepreneur will be able to directly engage ...
(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... start-ups Straw Fuels and AdFerTech have won prizes ... supported by the EU,s main climate innovation initiative, ... the Climate-KIC Early Stage Entrepreneurs Prize, which will ... of Climate-KIC,s pan-European start-up Acceleration Programme. Straw Fuels, ...
... Colo., USA GSA Bulletin postings ... as seen in the Pyrenees; facies architecture in ... Permian Maroon Formation; preglacial fluvial gorges and valleys; ... Africa; Ediacaran fossils from Mistaken Point, Newfoundland; geologic ...
... Increasing block-rate water budgets are an innovative type of ... sizes are based on household characteristics, environmental conditions, and ... what constitutes "efficient" water use given those characteristics and ... relatively low for the most essential uses of water ...
Cached Biology News:Liquor converter, BBQ logs win €20K prizes at UK innovation showcase 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 2Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 3Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 4Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 5Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 6Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 7Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 8Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 9Mistaken point, Sanctuary of Zeus, catastrophic outburst floods, shocked sand grains 10An innovative approach to promote water use efficiency 2An innovative approach to promote water use efficiency 3
... Exiqon's miRCURY LNA technology enables sensitive and ... blotting. miRCURY LNA Detection probes have high ... and sensitive detection of miRNAs. Due to ... LNA probes less than 1/10 the amount ...
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length Vitronectin protein (Mouse). Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... [PRMT5-21] to PRMT5 Arginine methylation is ... only recently been linked to protein activity. ... have been identified in mammalian cells. These ... regulatory functions by methylation of key proteins ...
... Kit uses a simplified procedure and streamlines ... The kit is based on the three ... and sodium bisulfite where cytosine is converted ... innovative in-column desulphonation reaction eliminates several precipitation ...
Biology Products: